News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Epic Sciences Awarded a Phase II SBIR Contract From National Cancer Institute/National Institutes of Health (NIH) to Develop a Lung Cancer Diagnostic Blood Test


1/24/2013 9:41:13 AM

SAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc., (“Epic”), a private biotech company that develops breakthrough cancer diagnostics, announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI) and the National Institutes of Health (NIH). The contract will fund the further development of an assay to identify and characterize circulating tumor cells (CTCs) in lung cancer patients. The results of this contract are expected to provide a basis for the development of new cancer diagnostic products.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES